Eupraxia Pharmaceuticals (EPRX) announced the company has filed a preliminary prospectus supplement to its short form base shelf prospectus dated February 5, 2024 in connection with a proposed public offering of common shares of the company. Cantor and LifeSci Capital are acting as joint book-running managers for the offering. Bloom Burton is also acting as co-manager for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Eupraxia Pharmaceuticals management to meet with Cantor
- Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald
- Eupraxia Therapeutics: Positive EP-104GI EoE Data, Strong Safety Profile, and Solid Cash Runway Support Buy Rating
- Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI
- Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial